drugset
drugset / Trial / NCT06856265

Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06856265 ↗

Not yet recruiting 40 enrolled Shanghai Chest Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of Mavacamten combined with radiofrequency ablation compared to Mavacamten alone in patients with symptomatic obstructive hypertrophic cardiomyopathy (HOCM). Participants were randomized into two groups:

Timeline

Start
2025-02-26
Primary completion
2025-12-01
Completion
2025-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavacamten Small molecule 1 mg Oral
Subject Mavacamten Small molecule 2.5 mg Oral
Subject Mavacamten Small molecule 5 mg Oral
Subject Mavacamten Small molecule 10 mg Oral
Subject Mavacamten Small molecule 15 mg Oral

Indications

hypertrophic cardiomyopathy